Mycosis fongoïde et syndrome de Sézary : revue systématique [Mycosis fungoides and Sézary syndrome : a systematic review]

Autor: André, F., Blanchard, G.

Publikováno v: Revue medicale suisse, vol. 18, no. 775, pp. 578-589

The two main subtypes of primary cutaneous T-cell lymphomas include the most frequent, mycosis fungoides (MF), and the rare leukemic variant, Sézary syndrome (SS). MF presents as cutaneous patches and can progress to plaques, tumors and erythroderma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1900::3adb1bd9912768bf48930daad388fa7f
https://serval.unil.ch/resource/serval:BIB_C5B73CBE2CDF.P001/REF.pdf

Mycosis fungoides and Sézary syndrome

Autor: Julia Tittes, Constanze Jonak, Patrick M. Brunner, Emmanuella Guenova

Publikováno v: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology, vol. 19, no. 9, pp. 1307-1334

Mycosis fungoides (MF) and Sezary syndrome (SS) are primary cutaneous T-cell lymphomas (CTCL) with not yet fully understood etiology and pathogenesis. Conceptually, MF and SS are classified as distinct entities arising from different T helper cell su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83edba75d80405c5876f9f8c88295872
https://pubmed.ncbi.nlm.nih.gov/34541796

Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany

Autor: Christian Posch, Veronica Aedo-Lopez, Julian Kofler, Julia Maria Ressler, Peter Koelblinger, Matthias Karasek, Christoph Hoeller, Christine Hafner, Helmut Kehrer, Olivier Michielin, Rita Silmbrod, Felix Weihsengruber, Erika Richtig, Lukas Koch, Sofiya Latifyan, Joanna Mangana

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for immunotherapy of cancer, vol. 9, no. 2, pp. e001701

BackgroundTalimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Pivotal Trial in Melanoma study, which als

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed27d867e0f6ae9e5fa254d7177dae2c
https://mediatum.ub.tum.de/1653382

Mélanome localement avancé et métastatique : nouveautés [Locally advanced and metastatic melanoma : novelties]

Autor: Huber, A., Latifyan, S., Nikolopoulou, A., Homicsko, K., Berthod, G., Michielin, O., Özdemir, B.C.

Publikováno v: Revue medicale suisse, vol. 16, no. 695, pp. 1092-1097

The standard of care of melanoma patients has evolved at a rapid pace with the advent of immune checkpoint inhibitors and BRAF and MEK inhibitors. ESMO guidelines were revised in September 2019 to integrate the results of recent studies that broaden

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1900::e0614dd2bd533d023c8ba709342a5cfe
https://serval.unil.ch/resource/serval:BIB_E5DDB348D97F.P001/REF.pdf

CART cells are prone to Fas- and DR5-mediated cell death

Autor: Benjamin O, Tschumi, Nina, Dumauthioz, Bastien, Marti, Lianjun, Zhang, Evripidis, Lanitis, Melita, Irving, Pascal, Schneider, Jean-Pierre, Mach, George, Coukos, Pedro, Romero, Alena, Donda

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-9 (2018)
Journal for immunotherapy of cancer, vol. 6, no. 1, pp. 71
Journal for Immunotherapy of Cancer

Adoptive transfer of T cells transduced with Chimeric Antigen Receptors (CAR) are now FDA-approved for the treatment of B-cell malignancies. Yet, the functionality of the endogenous TCR in CART cells has not been fully assessed. Here, we demonstrate

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a80bba75f1e73c794d100fc15277252
http://link.springer.com/article/10.1186/s40425-018-0385-z